Trial Profile
A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in a Dose-reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; Forest Laboratories
- 05 Oct 2022 Planned number of patients changed from 822 to 1755.
- 02 Oct 2022 This trial has been completed in Bulgaria, according to European Clinical Trials Database record (5 Sep 2022).
- 21 Sep 2022 Status changed from active, no longer recruiting to completed.